Literature DB >> 8073991

MR of cis-platinum-induced optic neuritis.

S H Mansfield1, M Castillo.   

Abstract

Right-sided blindness developed in a patient after three intraarterial treatments with cis-platinum for a right temporal glioblastoma multiforme. MR showed an enlarged and enhancing optic chiasm. Because of the history of remote radiation therapy and the fact that the tumor was located distal to the optic chiasm, we postulate that the clinical and imaging findings were related to the chemotoxicity.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8073991      PMCID: PMC8333469     

Source DB:  PubMed          Journal:  AJNR Am J Neuroradiol        ISSN: 0195-6108            Impact factor:   3.825


  5 in total

1.  Cyclin-dependent kinases and P53 pathways are activated independently and mediate Bax activation in neurons after DNA damage.

Authors:  E J Morris; E Keramaris; H J Rideout; R S Slack; N J Dyson; L Stefanis; D S Park
Journal:  J Neurosci       Date:  2001-07-15       Impact factor: 6.167

2.  Monocular visual loss in a patient undergoing cisplatin chemotherapy.

Authors:  F Gonzalez; D Menendez; F Gomez-Ulla
Journal:  Int Ophthalmol       Date:  2001       Impact factor: 2.031

3.  G1/S cell cycle blockers and inhibitors of cyclin-dependent kinases suppress camptothecin-induced neuronal apoptosis.

Authors:  D S Park; E J Morris; L A Greene; H M Geller
Journal:  J Neurosci       Date:  1997-02-15       Impact factor: 6.167

4.  The Chk1/Cdc25A pathway as activators of the cell cycle in neuronal death induced by camptothecin.

Authors:  Yi Zhang; Dianbo Qu; Erick J Morris; Michael J O'Hare; Steven M Callaghan; Ruth S Slack; Herbert M Geller; David S Park
Journal:  J Neurosci       Date:  2006-08-23       Impact factor: 6.167

5.  Cyclin-dependent kinases participate in death of neurons evoked by DNA-damaging agents.

Authors:  D S Park; E J Morris; J Padmanabhan; M L Shelanski; H M Geller; L A Greene
Journal:  J Cell Biol       Date:  1998-10-19       Impact factor: 10.539

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.